Skip to main content
. 2024 Feb 20;32(1):101216. doi: 10.1016/j.omtm.2024.101216

Figure 6.

Figure 6

Combination treatment with α-CD20 and extended α-BAFF allows re-administration following immune compartment repopulation

(A) Schematic outline of IS pretreatment regimens and AAV8 dosing. (B) Circulating plasma levels of OVA at 4 weeks post-AAV8-OVA administration (n = 5–10/group). AAV8 capsid-specific IgM (C) and IgG2c (D) Ab levels in plasma samples collected at different time points prior to AAV8-hFIX re-administration. AAV8 capsid-specific IgM (E) and IgG2c (F) Ab levels in plasma samples collected at different time points post-AAV8-hFIX re-administration. (G) Circulating hFIX levels at 4 weeks post-AAV8-hFIX re-administration. Statistical significance was calculated by one-way ANOVA (Dunnett’s multiple comparisons) for (B) and (G), and two-way ANOVA for (C)–(F). ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001.